Tenax Therapeutics, INC 8-K filings

Tenax Therapeutics has successfully priced a public offering to raise approximately $9 million, which will be used to advance its Phase 3 trial of oral levosimendan and for general corporate purposes.

Tenax Therapeutics has announced the enrollment of the first patient in its Phase 3 LEVEL study evaluating TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction.

Tenax Therapeutics has received a Notice of Allowance from the USPTO for a patent that significantly broadens intellectual property protection for levosimendan in treating Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

Tenax Therapeutics has regained compliance with Nasdaq's minimum bid price rule after its stock price closed above $1.00 for ten consecutive trading days.

Tenax Therapeutics received a delisting notice from Nasdaq due to insufficient publicly held shares and appointed an interim CFO following the passing of the previous CFO.